FDA Grants Breakthrough Therapy Designation to Oculis' Privosegtor for Optic Neuritis Treatment
核心洞察
The U.S. FDA has granted breakthrough therapy designation to Oculis' neuroprotective candidate Privosegtor for treating optic neuritis (搜索), a rare condition that can lead to permanent vision loss.
In the Phase 2 ACUITY trial, patients receiving Privosegtor 3 mg/kg/day plus IV methylprednisolone gained an average of 18 letters on visual acuity tests at three months compared to placebo.
Privosegtor represents the potential first neuroprotective therapy for optic neuropathies, addressing a market opportunity potentially exceeding $7 billion in the U.S. alone.
The U.S. Food and Drug Administration has granted breakthrough therapy designation to Oculis' neuroprotective candidate Privosegtor for the treatment of optic neuritis (搜索), marking a significant regulatory milestone for what could become the first approved therapy to protect vision in this rare neuro-ophthalmic condition.
The FDA's decision was supported by visual function results from the Phase 2 ACUITY trial, where Privosegtor demonstrated substantial improvements in low contrast visual acuity (LCVA) along with anatomical and biological benefits compared to placebo. Patients receiving Privosegtor 3 mg/kg/day plus IV methylprednisolone gained an average of 18 letters at three months compared with placebo plus IV methylprednisolone. For context, a 15-letter gain represents roughly a two-fold improvement in visual resolution and is considered clinically meaningful for daily visual functioning.
Clinical Trial Results Demonstrate Neuroprotective Potential
The ACUITY (Acute OptiC NeUrITis (搜索) of DemYelinating Origin) trial was a randomized, double-blind, placebo-controlled, multi-center study that evaluated once-daily intravenous infusion of Privosegtor over five days in patients with acute optic neuritis receiving steroids. The study randomized 36 eligible patients aged between 18 to 60, with recent onset of unilateral acute optic neuritis with a demyelinating origin, of which 33 patients received Privosegtor 2mg or 3 mg/kg/day plus IV methylprednisolone, or placebo plus IV methylprednisolone for five days.
Beyond visual improvements, Privosegtor showed anatomical preservation of retinal and optic nerve (搜索) structure, which are typically damaged during acute optic neuritis (搜索). Additional analyses revealed reduced neurofilament release, a biomarker of decreased neuroaxonal injury seen in conditions such as multiple sclerosis (搜索). The safety profile was favorable, with the most common drug-related adverse events being headache and acne (each in two participants; 10.5%). No drug-related serious adverse events or events leading to treatment or study discontinuations occurred.
"The ACUITY trial delivered truly groundbreaking results, demonstrating for the first time in a single study that a drug candidate consistently improves visual function alongside anatomical and biological evidence of neuroprotective benefit," said Mark Kupersmith, M.D., Chief Medical Advisor, Neuro-Ophthalmology at Oculis. "Significant unmet medical needs remain, as patients with optic neuritis (搜索)—more often young women and frequently experiencing the first sign of multiple sclerosis (搜索)—are still at high risk of permanent visual loss."
Addressing Significant Unmet Medical Need
Optic neuritis (搜索) is a rare condition characterized by acute inflammation of the optic nerve (搜索) that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. incidence estimated to be greater than 30,000 and often represents the first sign of multiple sclerosis (搜索). The condition mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1 ratio).
Currently, there is no specific therapy approved for acute optic neuritis (搜索), and the unmet need remains for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death. Privosegtor, a novel peptoid small molecule designed to cross both the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuropathies.
PIONEER Program Launches with Three Pivotal Trials
Following a successful meeting with the FDA in 2025, Oculis launched the PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes three pivotal trials to support registration plans for Privosegtor in optic neuritis (搜索) and a second rare neuro-ophthalmic disease, non-arteritic anterior ischemic optic neuropathy (NAION (搜索)). These two optic neuropathies represent a potential market opportunity potentially exceeding $7 billion in the U.S. alone.
The first trial in the program, PIONEER-1 in optic neuritis (搜索), was initiated in Q4 2025. This global study spans three continents, with sites activation underway and enrollment expected to begin shortly. PIONEER-2, also evaluating privosegtor in optic neuritis patients, is planned to begin in the first half of 2026. PIONEER-3 will evaluate privosegtor after the acute onset of NAION (搜索) and is planned for mid-2026.
NAION (搜索) is an acute optic nerve (搜索) disorder that causes permanent visual impairment in more than 60% of affected patients. It is the most common cause of acute optic nerve injury in individuals over 50 years old and affects up to 10.2 per 100,000 people worldwide with a U.S. incidence estimated to be greater than 30,000. There are no approved therapies for NAION.
Regulatory and Commercial Implications
The breakthrough therapy designation provides Oculis with more intensive FDA guidance on efficient drug development, organizational commitment involving senior managers, and eligibility for rolling review and priority review. This regulatory pathway is intended to expedite the review of drugs for serious or life-threatening conditions where preliminary clinical evidence demonstrates substantial improvement over available therapy.
"Today's Breakthrough Therapy Designation underscores Privosegtor's significant potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis (搜索), and highlights our commitment to redefining what's possible for patients suffering from neuroaxonal loss," stated Riad Sherif, M.D., Chief Executive Officer of Oculis. "With the ACUITY results and Privosegtor now progressing as a neuroprotective platform across key neuro-ophthalmic diseases, Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs."
Privosegtor has also received Orphan Drug designation from both the FDA and the European Medicines Agency for optic neuritis (搜索). The drug candidate could potentially have wide applicability in treating other neuro-ophthalmic and neurological indications beyond its current development programs.